The coronavirus booster might take the same path as the flu vaccine when it comes to uptake. They might wait until next flu season to go for another shot. Many of these people - if they aren't high-risk - probably feel sufficiently protected for now. These are the products that were available before the strain-specific boosters. adult population that got a primary series has gone for a first booster dose. But I'm still not overly worried about Moderna's future. Of course, all of this is unlikely to lead to a huge jump this year in the numbers of people opting for strain-specific boosters. So, we could see a peak in booster uptake in a few weeks as these people become eligible. Therefore, they may have to wait before getting the updated booster. Some of them may have received a booster a short while ago. Many of the most fragile people have gotten vaccination as frequently as possible. Second, the FDA has recommended the updated booster for those whose last coronavirus shot was at least two months ago. This may spur people to get booster shots at times outside of the usual fall season, at least for now. We have seen the biggest peaks in cases during the winter months.īut we've also seen smaller peaks during other times of the year - such as spring and summer. First, like flu, the coronavirus may eventually become seasonal. So, if we use this as a guide, it's clear that a very small percentage of the population has opted for the updated booster.īefore we get too worried about Moderna's fate, though, it's important to keep in mind a few points. The Centers for Disease Control and Prevention (CDC) generally recommends people go for flu shots before the end of October. Of the adults who have completed a primary vaccine series, less than 3% have opted for a Moderna booster so far. So, we'll look at the percentage of adults who have received Moderna's updated shot. But initially, the FDA gave the nod only for use in adults. Food and Drug Administration (FDA) recently extended its authorization of the booster to include people ages six and older. I'm talking about the number of people who have received Moderna's strain-specific booster. Could it mean trouble for Moderna? The strain-specific booster Still, one particular number doesn't look so brilliant. And the product made it to market in time for the fall vaccination season. Regulators gave the omicron booster a thumbs-up this summer. The biotech's next revenue driver is selling a strain-specific booster. But that doesn't mean Moderna's revenue opportunity is over. Today, most of the people who wanted the primary vaccine series have gotten it. Moderna ( MRNA 1.57%) generated billions of dollars from its sale of coronavirus vaccines earlier in the pandemic.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |